Mellinghoff, Sibylle C. http://orcid.org/0000-0003-3928-2503
Robrecht, Sandra
Mayer, Leonie http://orcid.org/0000-0001-7102-4358
Weskamm, Leonie M. http://orcid.org/0000-0002-1175-7354
Dahlke, Christine http://orcid.org/0000-0002-2056-9195
Gruell, Henning http://orcid.org/0000-0002-0725-7138
Vanshylla, Kanika
Schlösser, Hans A.
Thelen, Martin http://orcid.org/0000-0002-2785-9726
Fink, Anna-Maria http://orcid.org/0000-0002-7669-7890
Fischer, Kirsten
Klein, Florian
Addo, Marylyn M. http://orcid.org/0000-0003-2836-9224
Eichhorst, Barbara
Hallek, Michael
Langerbeins, Petra http://orcid.org/0000-0002-6654-0304
Article History
Received: 8 November 2021
Revised: 2 December 2021
Accepted: 10 December 2021
First Online: 22 December 2021
Competing interests
: SCM reports grants from DZIF (Clinical Leave Stipend). AMF reports research funding from Celgene/Bristol Myers Squibb (Inst), AstraZeneca (Inst), and travel Expenses by AbbVie. KF reports other from Roche, other from AbbVie. BE reports grants and personal fees from Janssen-Cilag, grants and personal fees from Roche, personal fees from Novartis, grants and personal fees from AbbVie, personal fees from Celgene, personal fees from ArQule, personal fees from AstraZeneca, personal fees from Oxford Biomedica (UK), grants and personal fees from Gilead, grants from BeiGene, outside the submitted work. MH reports other from AbbVie, other from F. Hoffman-LaRoche, other from Gilead, other from Janssen-Cilag, other from Mundipharma, during the conduct of the study. PL reports grants and personal fees from Janssen-Cilag, personal fees from Abbvie, other from F. Hoffman-LaRoche, personal fees from AstraZeneca. The remaining authors declare no competing financial interests for this study.